PDB92 Impact Of Oral Medication Adherence And Lab Testing On Five-Year Total Medical Costs In A Commercially Insured Diabetic Population  by Couto, JE et al.
A172 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
with hypoglycemia ED visits was in a declining trend of 2005-2009 and the lowest 
in 2009 (n=71,751). Consequently, the estimated annual expenditure of hospital 
admission from ED declined each year from 2005 ($2.90 billion) to 2009 ($1.25 
billion). The expenditure of hypoglycemia visits to ambulatory facilities 
fluctuated between 0.37 million in 2007 and 1.08 million in 2008, resulting in the 
estimated annual cost of approximately $80.46 million to $229.03 million, 
respectively. CONCLUSIONS: Annual direct medical cost associated with 
hypoglycemia in the U.S. was $3.49 billion in 2005 and declined to $1.84 billion in 
2009. The trend may be attributed to improvements in patient education, glucose 
monitoring, and new anti-diabetic medications with lower risk for hypoglycemia.  
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IMPACT OF MEDICARE PART D: COMPARISON OF HEALTH CARE EXPENDITURES 
AND UTILIZATION FOR MEDICARE PATIENTS WITH DIABETES  
Majercak K, Li C 
University of Arkansas for Medical Sciences, Little Rock, AR, USA  
OBJECTIVES: To compare overall and diabetes-related health care utilization and 
expenditures in Medicare beneficiaries with diabetes prior to and after 
implementation of Part D. METHODS: Data were from the 2001-2010 Medical 
Expenditure Panel Survey. Medicare beneficiaries aged ≥65 years with self-
reported diabetes were identified, excluding individuals who were Medicare-
Medicaid dual eligible, had TRICARE, or other public coverage. The outcomes 
included overall and diabetes-related prescriptions, medical services utilization, 
and expenditures as well as out-of-pocket costs. These outcomes were analyzed 
using generalized linear model regression models with a log-link and gamma (for 
costs) or Poisson (utilization) distribution. All expenditures were inflated to 2010 
dollars. STATA survey commands were used to account for the complex survey 
design. RESULTS: There were 21,864 eligible Medicare beneficiaries with diabetes 
that comprised the sample population. After adjusting for sociodemographic 
characteristics and health status, implementation of Part D was associated with 
decreased out-of-pocket expenditures for insulin (Coeff.: -0.577, p<0.05) and oral 
antidiabetic agents (Coeff.:-1.292, p<0.001). No statistically significant effect on 
total health care and prescription expenditures were found. Implementation of 
Part D was associated with increased number of prescriptions filled (Coeff.: 0.145, 
p<0.001) without increase in emergency room visits or inpatient stays. 
CONCLUSIONS: The implementation of Medicare Part D increased medication 
use and reduced out-of-pocket costs for elderly diabetes patients. This reduction 
would allow for enhanced access to necessary medications, and thereby may 
have a positive impact on adherence and health outcomes.  
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FACTORS ASSOCIATED WITH PRESCRIPTION DRUG EXPENDITURE IN PATIENTS 
WITH DIABETES MELLITUS: AN ANALYSIS OF MEDICAL EXPENDITURE PANEL 
SURVEY, 2005-2009  
Medhekar RA1, Franzini L2 
1University of Houston, Houston, TX, USA, 2The University of Texas School of Public Health, 
Houston, TX, USA  
OBJECTIVES: To determine the factors associated with prescription drug 
expenditure in patients with Diabetes Mellitus in the United States (US). 
METHODS: A retrospective cross-sectional study was conducted using the 2005-
2009 Medical Expenditure Panel Survey (MEPS) data, a nationally representative 
data on non-institutionalized US population. The study sample included diabetic 
patients identified using the diabetes diagnosis variable reported in the MEPS 
data and the ICD-9CM code: 250. Descriptive statistics were performed on the 
weighted sample to estimate the average prescription drug expenditure for 
patients with Diabetes. The Anderson Behavioral Model was used as the 
theoretical framework to identify factors associated with prescription drug 
expenditure and Ordinary Least Square regression was used for analysis. The 
prescription drug expenditure was log transformed to address skewed nature of 
cost data. RESULTS: An estimated 97 million patients were diagnosed with 
Diabetes Mellitus during 2005-2009. The average prescription drug expenditure 
for these patients was $3088 per year (95% CI: 2977-3199). The linear regression 
revealed that predisposing (age, race, marital status and employment status), 
enabling (region, health insurance coverage, prescription insurance coverage and 
usual source of care) and need (Charlson comorbidity index and general health 
status) characteristics were significantly associated with prescription drug 
expenditure. One year increase in age increased expenditure by 1.1%. Non-
Hispanic blacks had 33% higher expenditure than other races. Patients with 
health insurance coverage, prescription insurance coverage and usual source of 
care had 54%, 13% and 69% higher expenditure respectively as compared to 
those without these benefits. Charlson comorbidity index was positively 
associated with prescription drug expenditure. Patients with poor/fair self-
reported health status had 61% higher expenditure than other patients. 
CONCLUSIONS: Predisposing and enabling factors like race, employment, health 
and prescription insurance coverage and usual source of care had significant 
impact on prescription expenditure despite controlling for health status and 
need characteristics.  
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ADHERENCE TO INSULIN THEAPY MAY SUBSTANTIALLY REDUCE COSTS 
ASSOCIATED WITH HEALTH RESOURCE UTILIZATION AMONG INSULIN PEN 
USERS WITH TYPE II DIABETES MELLITUS  
Chandran A1, Bonafede MM2, Saltiel-Berzin R1, Hirsch LJ1, Lahue BJ1 
1BD, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To evaluate the impact of adherence to insulin therapy on health 
resource utilization (HRU) among patients with type 2 diabetes mellitus (T2DM) 
using an insulin pen. METHODS: The Truven Health MarketScan Research 
Database was used to identify patients with ≥1 one insulin pen claim between 
January 2006 and September 2010 with continuous enrollment for 12 months 
after that claim, had a diagnosis of T2DM and one prescription for an oral anti-
diabetic drug. Patient demographics, clinical characteristics, health care 
expenditures and medication (insulin pen) possession ratios (MPR) were also 
analyzed. Total costs were calculated by summing the patient and payer 
portions of all post-index health insurance claims. MPR was calculated using the 
days supply field of the insulin prescription claims, adjusted to account for 
variations in time between insulin refills. RESULTS: 32,361 patients met the 
study criteria. On average patients were 59.1 (SD=11.6) years old and 52.4% were 
male; 97.1% of the sample had capitated, non-capitated or a fee-for-service 
health plan (2.8% unknown). The baseline Charlson comorbidity score was 2.0 
(SD=1.7). The most common comorbidities included hypertension (46.7%), 
dyslipidemia (31.3%), ischemic heart disease (23.4%), diabetic neuropathy (19.6%), 
and renal disease (15.9%). Concomitant medication use was prevalent with at 
least one quarter of the sample filling a prescription for one or more of the 
following: sulfonylureas (27.1%), antidepressants (30.9%), biguanides (48.4%), 
antihyperlipidemics (77.8%) and antihypertensives (87.0%). All-cause 
expenditures for insulin pen users during the study period were $24,680 
(SD=$44,005). Average sample MPR was 0.63 (SD=0.29). When broken into 
quintiles there is a significant difference in health care expenditures between 
the least adherent (MPR 0-0.20, $26,310) and most adherent groups (MPR 0.81-
1.00, $23,839) (p=0.007). CONCLUSIONS: Managing patient adherence may 
present an opportunity to curb health resource utilization in T2DM insulin pen 
users.  
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ECONOMIC OUTCOMES ASSOCIATED WITH HBA1C AND LDL-C GOAL 
ACHIEVEMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS  
Shi L1, Ye X2, Lu M3, Wu EQ3, Sharma H3, Thomason D3, Fonseca V1 
1Tulane University, New Orleans, LA, USA, 2Daiichi Sankyo, Parsippany, NJ, USA, 3Analysis 
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OBJECTIVES: To examine the economic outcomes associated with dual-goal 
achievement of reaching glycated hemoglobin (HbA1c <7%) and low-density 
lipoprotein cholesterol (LDL-C <100mg/dL) targets in patients with type 2 
diabetes mellitus (T2DM). METHODS: Adult T2DM patients (ICD-9 codes: 250.x0, 
250.x2) were identified from the South Central Veterans Affairs Health Care 
Network (01/2004-06/2010) and followed until the end of data or death. A 
longitudinal design was adopted with patient information recorded in six-month 
cycles. Goal achievement status in each cycle was determined based on the 
average HbA1c and LDL-C levels using the area under the curve method. 
Economic outcomes included diabetes-related utilization events (inpatient (IP) 
days, number of outpatient (OP) visits) and diabetes-related medical service 
costs. The association between goal achievement status in a given study cycle 
and economic outcomes in the following cycle were assessed using multivariate 
generalized linear models, controlling for within-patient correlation. RESULTS: A 
majority of the 75,646 patients selected for the study were male (97.4%); average 
age was 64.7 years, mean BMI was 31.6 kg/m2, and median follow-up time was 
4.5 years. Compared with achievement of only the LDL-C goal, dual-goal 
achievement was associated with significantly fewer diabetes-related IP days 
(Incidence Rate Ratio (IRR): 0.93; 95% Confidence Interval (CI): 0.87-1.00), and OP 
visits (IRR: 0.88; CI: 0.87-0.89), and incurred significantly lower diabetes-related 
medical service costs (difference: -$130.89, p=0.02). Compared with achievement 
of only the HbA1c goal, dual-goal achievement was associated with significantly 
fewer OP visits (IRR: 0.98; CI: 0.97-1.00) but no statistical difference in the number 
of hospitalization days (IRR: 0.98, CI: 0.89-1.07) or diabetes-related medical 
service costs (difference:-$56.17, p=0.40). CONCLUSIONS: In this study of US 
Veterans with T2DM, dual-goal achievement was associated with fewer 
utilization events and lower costs when compared with only LDL-C goal 
achievement.  
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IMPACT OF ORAL MEDICATION ADHERENCE AND LAB TESTING ON FIVE-YEAR 
TOTAL MEDICAL COSTS IN A COMMERCIALLY INSURED DIABETIC 
POPULATION  
Couto JE, Xu C, Nguyen HV, Bunz TJ 
Cigna, Bloomfield, CT, USA  
OBJECTIVES: The primary aim was to examine the economic outcomes 
associated with long-term adherence to oral diabetes medications in the 
Diabetes Mellitus (DM) population. The secondary aim was to examine the 
economic outcomes associated with having a history of an HbA1c test during the 
study period. METHODS: Patients continuously enrolled from January 01, 2006 to 
December 31, 2011 and did not have a diabetes diagnosis or medication one year 
prior to the index date were eligible for inclusion in this retrospective study 
(N=2090). Patients who had at least two oral diabetes medication fills in the 
index year, had an integrated medical and pharmacy benefit, and who did not 
have any injectable medications during the study period were stratified to 
examine the primary aim (N=781). Patients were defined as adherent if they had 
a medication possession ratio (MPR) of greater than 80% in all five years (N=153), 
the remainder were classified as non-adherent (N=628). To quantify the 
economic outcomes associated with a history of an HbA1c test, patients were 
stratified based on a history of HbA1c test. RESULTS: Compared to the non-
adherent group, the adherent group had lower unadjusted mean medical costs. 
The five-year total medical costs were $25,726 in the non-adherent group and 
$22,153 in the adherent group, a 16% difference (p≤0.05). A similar difference was 
observed when comparing inpatient and emergency room costs ($8694 vs. $5268, 
p≤0.001) Compared to patients without an HbA1C test during the study period 
(N=792), patients with an HbA1c test (N=1298) had lower total medical costs 
($36,599 vs. $29,153 respectively, p≤0.05) and inpatient and emergency room 
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costs ($14,380 vs. $9,800 respectively, p≤0.05). CONCLUSIONS: Diabetes patients 
with consistently high medication adherence to oral medications or having a 
history of an HbA1c test over a five-year period had lower medical costs and 
lower inpatient and emergency room costs than their counterparts.  
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CLINICAL CHARACTERISTICS, QUALITY MEASURE ATTAINMENT, AND 
DIABETES-RELATED HEALTH CARE COSTS IN ELDERLY VERSUS OVERALL 
PEOPLE LIVING WITH TYPE-2 DIABETES MELLITUS (T2DM) RECEIVING 
METFORMIN (MET) AND SULFONYLUREA (SU)  
Lafeuille MH1, Gravel J1, Bailey RA2, Martin S2, Garber L3, Duh MS4, Lefebvre P1 
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 
3Reliant Medical Group, Worcester, MA, USA, 4Analysis Group, Inc., Boston, MA, USA  
OBJECTIVES: This study examined the demographics, comorbidities, clinical 
characteristics, and treatments of people with T2DM and an elderly subgroup. 
Additionally, attainment of quality goals and its correlation with diabetes-related 
costs were assessed. METHODS: Health insurance claims and electronic medical 
records from 14,532 adults with T2DM (2007-2011) were used to identify a sample 
receiving MET+SU. The index date was defined as the first dispensing of MET+SU 
after 6 months of eligibility. Clinical characteristics were assessed during 
baseline and quality measure attainment, defined as no values above specific 
thresholds (HbA1c <8%, body mass index [BMI] <30 kg/m2, blood pressure [BP] 
<140/90 mmHg, low-density lipoprotein cholesterol [LDL-C] <100 mg/dL), was 
evaluated during a 12-month landmark period after the index date. Association 
between quality measure attainment and diabetes-related costs, calculated after 
the landmark period, was evaluated using non-parametric bootstrap methods 
adjusting for imbalance in baseline characteristics between cohorts. RESULTS: 
2,044 patients (mean age: 67 years; female: 46%), including 1,283 (62.8%) patients 
≥65 years, were identified. Baseline comorbidities included cardiovascular 
disease (all patients: 25.5%; ≥65 years: 33.4%), congestive heart failure (5.9%; 
8.1%), hypertension (66.5%; 74.2%), hyperlipidemia (73.9%; 78.1%), and 
neuropathy (16.0%; 20.2%). Statins and loop and non-loop diuretics were taken by 
60.5%, 10.5%, and 21.1% of all patients, and 66.9%, 13.8%, and 24.5% of patients 
≥65 years, respectively. The proportions meeting various quality goals were: 
82.9% (≥65 years: 88.2%) for HbA1c, 34.4% (42.1%) for BMI, 31.6% (27.7%) for BP, 
and 68.2% (73.3%) for LDL-C. Quality measure attainment was associated with 
significantly lower diabetes-related costs per-patient per-year (adjusted mean 
cost differences: -$1,445 for HbA1c; -$1,218 for BMI; -$2,029 for HbA1c and BMI;  
-$2,073 for HbA1c, BMI, and BP; all P<0.05) compared to non-attainment. 
CONCLUSIONS: This study highlights the high incidence of comorbidities and 
potential financial benefits of attaining T2DM quality outcomes at the population 
level.  
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BURDEN OF HEALTH RESOURCE UTILIZATION (HRU) AMONG INSULIN PEN 
USERS WITH TYPE 2 DIABETES MELLITUS  
Chandran A1, Bonafede MM2, Saltiel-Berzin R1, Hirsch LJ1, Lahue BJ1 
1BD, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To characterize type 2 diabetes mellitus (T2DM) patients’ newly 
initiating insulin therapy with an insulin pen and quantify their health resource 
utilization (HRU). METHODS: Adult patients with at least one new claim for an 
insulin pen between January 2006 and September 2010 were selected from the 
Truven Health MarketScan Research Databases. Patients required continuous 
enrollment for 12 months after the index insulin pen claim, with a diagnosis of 
T2DM and one prescription for an oral antidiabetic drug. Frequency and cost of 
health care encounters were highlighted. HRU includes inpatient admissions, 
emergency department and outpatient office visits, outpatient laboratory and 
radiology services, other outpatient services and outpatient prescriptions. HRU was 
calculated separately for all-cause and diabetes-related expenditures. RESULTS: 
Nine thousand two hundred and eighty five patients met the study criteria with 
average age of 58.5 (SD=12.4); 52.9% were male. The Deyo-Charlson comorbidity 
score for this sample was 2.3 (SD=1.8). Most frequently observed baseline 
microvascular and macrovascular complications included diabetic neuropathy 
(14.7%), renal disease (16.2%), and ischemic heart disease (22.9%). Other common 
comorbidities included hypertension (47.3%) and dyslipidemia (31.5%). Patients 
frequently continued to fill oral anti-diabetic prescriptions after initiating an insulin 
pen, most commonly biguanides (46.3%) or sulfonylureas (31.8%). Concomitant 
medication use was high: most patients (83.9%) used a hypertensive, dyslipidemia 
(72.7%), anti-depressant (28.7%), or anti-emetic/nausea (9.6%) medication in the year 
after insulin pen initiation. In the year after insulin pen initiation, all-cause 
expenditures averaged $26,193 (SD=$47,670)), of which 15.8% were diabetes-related. 
Inpatient admissions accounted for 27.3% of total costs. Medication costs were 
substantial, accounting for 27.6% of total costs; 39.8% of medication costs were 
diabetes-related. CONCLUSIONS: Health expenditures associated specifically with 
T2DM patients initiating an insulin pen are substantial. Further research is required 
to explore the relationship of T2DM medication management on overall health 
resource utilization.  
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EVALUATION OF POLYPHARMACY IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS AND ITS ASSOCIATION WITH MEDICATION ADHERENCE AND 
HEALTH CARE COSTS  
Chen SY1, Alas V1, Lee YC1, Greene M2, Oderda G3 
1United BioSource Corporation, Lexington, MA, USA, 2Georgia State University, Atlanta, GA, 
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OBJECTIVES: To assess level of polypharmacy in patients with type 2 diabetes 
mellitus (T2DM) and its association with adherence to oral anti-diabetic drugs 
(OAD) and health care costs. METHODS: The Thomson MarketScan Commercial 
and Laboratory Databases 2005-2012 were used to select T2DM patients aged 18-
64 with continuous enrollment ≥2 years (the first year as baseline) who used 
OADs. Prescriptions at baseline year with at least 90 days of cumulative days-of-
supply were counted to determine level of polypharmacy according to active 
ingredient. Patients were categorized into four cohorts: no polypharmacy (≤2 
drugs), minor (3-5 drugs), moderate (6-8 drugs), and major (≥9 drugs). Adherence 
to OADs was evaluated during 12-months follow-up using mean proportion of 
days covered (PDC). Adjusted association between polypharmacy and adherence 
(PDC ≥0.8) to OAD and total health care costs were examined using logistic 
regressions and generalized linear regression models, respectively. RESULTS: Of 
the total sample population (N=13,365), 22.4% had non-polypharmacy, 39.3% had 
minor, 25.3% had moderate, and 13.0% had major polypharmacy. The 
polypharmacy cohorts had significantly higher all-cause health care costs (non-
polypharmacy: $7,482; minor: $9,144; moderate: $14,465; major: $25,072; all 
p<0.05) and adherence to OADs (non-polypharmacy: 42.0%; minor: 63.1%; 
moderate: 73.9%; major: 78.3%; all p<0.05) during the post-index period 
compared to non-polypharmacy. Annual incremental costs associated with 
polypharmacy were $1,602 (minor), $5,808 (moderate), and $13,447 (major) when 
compared with non-polypharmacy cohort. A higher level of polypharmacy was 
associated with a higher likelihood of adherence than the non-polypharmacy 
cohort (minor: OR=2.18, 95% CI=1.99-2.40; moderate: OR=3.58, 95% CI=3.20-3.99; 
major: OR=4.70, 95% CI=4.07-5.43). CONCLUSIONS: Polypharmacy was common 
and associated with high economic burden among patients with T2DM. The 
positive association between polypharmacy and adherence to OAD warrants 
further investigation of the behavioral mechanism.  
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PREVALENCE AND RISK FACTORS OF DIABETIC PERIPHERAL NEUROPATHY IN 
TYPE 2 DIABETES MELLITUS OUT-PATIENTS  
Gudala K1, Bansal D1, Muthyala H1, Bhansali A2 
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OBJECTIVES: The primary objective was to assess the prevalence of DPN using 
Vibration Perception Threshold (VPT) using biothesiometer considered as the 
gold standard for the diagnosis of DPN. The secondary objectives of the study 
were to compare the prevalence between Known Diabetics (KD) and Newly 
Detected Diabetics (NDD), assess the neuropathy prevalence pattern and identify 
any modifiable risk factors associated with occurrence of DPN among diabetics. 
METHODS: The study was cross-sectional, observational study. Subjects were 
recruited from Endocrinology clinic of a public tertiary care hospital. Subjects 
with duration of diabetes (≤6 months) were considered to be NDD. VPT 
measurements were done to assess neuropathy (cut off ≥20V). Severity of 
neuropathy was graded into three groups based on VPT score as mild (20- 24.99 
V), moderate (25-39 V), and severe (>39 V). 791 subjects were included on a 
random sampling basis which includes 638 KD and 153 NDD. Multivariate 
analysis was performed for assessing independent risk factors associated. 
RESULTS: The median duration of diabetes was found to be 6 (2 - 12) years. 300 
subjects were found to have DPN accounting for 37.9% (95%CI: 34.5-41.4) 
prevalence. Higher prevalence was observed in KD compared to ND (43.7% Vs 
13.7%, p<0.001). The prevalence of mild neuropathy was 10.4%, moderate 
neuropathy was 18.9%, and severe neuropathy was 8.6%. Regression analysis has 
shown age (p=0.007), female gender (p=0.001), duration of diabetes (p=0.001), 
dyslipidemia (p=0.008) and presence of other microvascular complication 
(p<0.001) to be associated with DPN occurrence among diabetics. CONCLUSIONS: 
This cross-sectional study shows the prevalence of DPN to be 37.9%. Severe 
neuropathy prevalence was found to be 8.6% who were at the risk of foot 
ulceration or lower limb amputation. DPN was associated significantly with 
increasing age, early onset of diabetes, female gender and dyslipidemia.  
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HEALTH CARE COSTS AND CLINICAL OUTCOMES ASSOCIATED WITH RATES 
OF SULFONYLUREA USE BY PHYSICIANS  
Bognar K1, Bell K2, Lakdawalla DN3, Shrestha A1, Snider JT1, Thomas N2, Goldman DP3 
1Precision Health Economics, Los Angeles, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 
3University of Southern California, Los Angeles, CA, USA  
OBJECTIVES: To study the association between rates of sulfonylurea (SU) use at a 
physician’s practice and average health care costs and complication rates among 
the physician’s patients with type 2 diabetes mellitus (T2DM). METHODS: We 
performed a retrospective group-level analysis on a sample of 7,905 patients 
(214,230 patient-months) insured by Humana, aged 18-64 with an incident T2DM 
diagnosis between 2007 and 2011. We regressed physician-level monthly 
complication rates (cardiovascular, lower extremity, ophthalmic, renal, 
neuropathy, and hypoglycemia) and average health care costs on 3-month-
lagged rates of SU use controlling for use of 10 other T2DM therapy classes in 
each physician’s practice, and patient and practice characteristics. Costs  
were estimated using a generalized linear model with log link to account for 
common zero costs. RESULTS: SU use was associated with increased rates of 
lower extremity, ophthalmic, and renal complications relative to no drug  
use (p<0.05). For each complication class, we identified the best performing 
therapy and estimated the effect of a hypothetical switch in prescribing patterns 
from 100% use of this class to 100% use of SU, as percentages of the respective 
average complication rates. Our estimates were: 93% increase in cardiovascular 
when switching from meglitinides, 133% increase in lower extremity when 
switching from alpha glucosidase inhibitors (AGI), 433% increase in ophthalmic 
when switching from amylinomimetics, 47% increase in renal when switching 
from biguanides, 147% increase in neuropathy when switching from AGIs and 
252% increase in hypoglycemic complications when switching from 
amylinomimetics. Despite SU’s association with higher complication rates, the 
